Herbert Y. Meltzer - Concepedia

Author

Herbert Y. Meltzer

Also Known As

&NA;, Brinda Umberköman-Wiita, H MELTZER, H Meltzer, H Meltzer, M.D., H Y Meltzer, H. Meltzer, H. Y. MELTZER, H. Y. Meltzer, H.Y Meltzer

1.1K

Publications

62K

Citations

120

H-Index

328

Concepts

All Affiliations

Vanderbilt University University of Chicago Case Western Reserve University Northwestern University Centre for Addiction and Mental Health

About

Herbert Y. Meltzer is an author at Vanderbilt University specializing in medicine, psychiatry, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	91	471	34.8K
2	Health Sciences	17	21	771
3	Education	2	2	29
4	Business	1	1	12
5	Management	1	1	12

Herbert Y. Meltzer

614

Publications

50.1K

Citations

113

H-Index

Page 1

	Year	Citations
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗∗See accompanying Editorial, in this issue. Grażyna Rajkowska, José Javier Miguel-Hidalgo, Jinrong Wei, Biological Psychiatry PsychiatryNeuroanatomyDepressionMood SpectrumSocial Sciences	1999	1.5K
Clozapine Treatment for Suicidality in Schizophrenia<subtitle>International Suicide Prevention Trial (InterSePT)</subtitle> Herbert Y. Meltzer Archives of General Psychiatry	2003	1.4K
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Herbert Y. Meltzer, Shin Matsubara, J C Lee Journal of Pharmacology and Experimental Therapeutics	1989	1.4K
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Joseph P. McEvoy, Jonathan M. Meyer, Donald Goff, Schizophrenia Research Intervention EffectivenessMetabolic SyndromeMetabolic DisorderPsychiatryPsychotic Disorder	2005	1.1K
H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs Wesley K. Kroeze, Sandra J. Hufeisen, Beth A Popadak, Neuropsychopharmacology Psychoactive DrugAtypical Antipsychotic DrugsPsychiatryMedicinePsychotropic Medication	2003	782
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment Joseph P. McEvoy, Jeffrey A. Lieberman, T. Scott Stroup, American Journal of Psychiatry PsychiatryPsychotic DisorderPsychotropic MedicationRebound EffectClinical Trials	2006	748
Cellular changes in the postmortem hippocampus in major depression Craig A. Stockmeier, Gouri Mahajan, Lisa C. Konick, Biological Psychiatry NeuropsychologyPsychiatryMood SymptomSubcortical Ischemic DepressionMajor Depression	2004	719
Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression Michaël Maes, Herbert Y. Meltzer, Eugène Bosmans, Journal of Affective Disorders InflammationPlasma ConcentrationsPsychoneuroimmunologyStress HormonePsychiatry	1995	625
5‐HT<sub>2A</sub> and D<sub>2</sub> receptor blockade increases cortical DA release via 5‐HT<sub>1A</sub> receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release Junji Ichikawa, Hideo Ishii, Stefania Bonaccorso, Journal of Neurochemistry	2001	492
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial Richard S.E. Keefe, Robert M. Bilder, Philip D. Harvey, Neuropsychopharmacology Catie Schizophrenia TrialNeuropsychological FunctioningNeuropsychologyPsychiatryPsychotic Disorder	2006	467

Page 1